Dermatology Advisor3d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Physician's Weekly4d
Using Targeted Interventions to Elevate QOL & Symptom Control in Plaque Psoriasis
Recent study findings highlight the value of integrating behavioral modification and Health Belief Model–based education into ...
WebMD2y
Plaque Psoriasis in Different Skin Tones
Plaque psoriasis misdiagnosis is common in people of color. Learn the reasons why, how it can affect your health, and what you can do to get better care.
pharmaphorum6y
FDA approves UCB’s Cimzia in plaque psoriasis
The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...
Healio21d
Oral TYK2 inhibitor has ‘outstanding efficiency’ in plaque psoriasis
Once-daily ICP-488 significantly improved PASI scores in patients with plaque psoriasis compared with placebo at week 12. The safety profile of ICP-488 was similar to placebo. ORLANDO — A once ...
Healio27d
New 5-year data showcase Sotyktu’s long-term efficacy, safety for plaque psoriasis
Bristol Myers Squibb has released new 5-year results from the long-term trial evaluating Sotyktu for the treatment of adults with moderate to severe plaque psoriasis, according to a press release.
WebMD2y
Improving Inclusivity in Medical Training
Plaque psoriasis brings extra challenges when you’re a person of color. These tips can help you partner with your doctor for the best care possible. See More on Psoriasis From WebMD ...